The severity and emergency of SARS-CoV-2 infection spurs an urgent need for antiviral drug and vaccine discovery. Creative Biolabs has spent considerable efforts to provide scientific support and comprehensive services to promote the success of this combat.
Equipped with cutting-edge techniques and vast experience, Creative Biolabs is keeping up with current research hotspots and integrating all resources to guarantee high-quality services (including but not limiting to): Antiviral Drug Discovery, Vaccine Discovery, Evaluation Platforms, In Vitro Diagnostic (IVD) Immunoassays.
https://sars-cov-2.creative-biolabs.com/novel-coronavirus-sars-cov2.htm
2. End of 2019 - Wuhan, China
Now – Spread in over 200 countries (WHO)
January 30, 2020 - PHEIC February 11, 2020 - Named SARS-CoV-2
January, 2020 - Named 2019-nCoV
SARS-CoV-2 Outbreak Process
3. Mammals Birds and
Mammals
The SARS-CoV-2 virus that causes COVID-19 belongs to the
Coronaviridae family.
SARS-CoV-2
Coronaviruses Family
4. Spike Glycoprotein (S)
Get the virus into the cell
Hemagglutinin-esterase (HE)
May facilitate the virus to initially adsorb
the cell membrane
RNA and N Protein
N protein is related to the formation of
nucleocapsid in RNA genome
E-Protein
The smallest and most mysterious
Envelope
SARS-CoV-2 Structure
M-Protein
Virus germination and envelope formation
6. Screen the existing broad-spectrum
antiviral drugs.
Use existing molecular libraries and
databases to screen for molecules that may
have a therapeutic effect on SARS-CoV-2.
Develop specific drugs based on the
genomic information and pathological
characteristics of SARS-CoV-2.
1 2 3
SARS-CoV-2 Treatment Strategies
7. 3-1. Target to the Host
• Enhance immune response - such as the
release of interferon.
• Block the signal pathways
required for virus replication.
• Target viral and cell surface receptor
proteins (ACE2).
Object of Specific Drugs
8. • Prevent viral RNA synthesis - target
to the genetic material of the virus.
• Inhibit virus replication - target to
key enzymes of the virus.
• Block the virus’s binding to human
cell receptors or inhibiting the
virus’self-assembly process - target
to the structural proteins of the virus.
Object of Specific Drugs
3-2. Target to SARS-CoV-2
9. Monoclonal antibody/convalescent plasma for ACE2:
Prevent the virus into the host cell.
1
science.sciencemag.org/content/367/6485/1412
Camostat mesylate: Prevent SARS-CoV-2 into the cell
by acting on TMPRSS2.
2
Lopinavir-Ritonavir: Inhibition of protease activity of
SARS-CoV-2.
3
Ribavirin- May inhibit mRNA capping.
4
RNA Synthesis Inhibitors: Inhibits SARS-CoV-2 RNA
synthesis and replication.
5
Neuraminidase Inhibitors (NAIs)-Interfere with the
release of progeny influenza virus from infected
host cells.
6
6
SARS-CoV-2 Treatment Strategies
NAIs
RNA Synthesis
Inhibitors
①
②
③
④
⑤
⑥
10. SARS-CoV-2 Preclinical Research
Drug Discovery Services
In Vitro Diagnostic (IVD) Development
• Anti-SARS-CoV-2 Drug Discovery
• Antibody & Immunoassay Development Services
Creative Biolabs’ SARS-CoV-2 Services
• SARS-CoV-2 Vaccine Discovery
• SARS-CoV-2 Preclinical Research
• Molecular Diagnostic Assay Development Services
• SARS-CoV-2 Related Detection Kits